Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Awareness and Attitude among Physicians Regarding Bisphosphonaterelated Osteonecrosis of the Jaw (BRONJ): A Cross-sectional Study

Author(s): Vidya Priyadarshini*, Srinivas Sulugodu Ramachandra and Aruna Ganganna

Volume 18, Issue 3, 2023

Published on: 20 August, 2022

Page: [361 - 367] Pages: 7

DOI: 10.2174/1574886317666220514160507

Price: $65

Abstract

Background: An invasive dental procedure is considered one of the risk factors for osteonecrosis of the jaw, especially among patients on bisphosphonates. This study aimed to determine the awareness and perceptions of medical practitioners regarding bisphosphonate-related osteonecrosis of the jaw (BRONJ), and their attitude towards dental referrals of such patients.

Methods: This cross-sectional questionnaire-based study was conducted among medical practitioners in and around Mysore city, Karnataka, India, who commonly prescribe bisphosphonates. The sample included orthopaedic doctors, physicians, endocrinologists, and oncologists, divided based on the duration of practice and speciality. Data on the type of practice, awareness of BRONJ, referral to a dentist before/during therapy, and patient education about adverse effects, were collected and analyzed. A p-value ≤0.05 was considered statistically significant.

Results: Among 58 practitioners, 84.5% (49) were aware of the association between bisphosphonates and BRONJ, while 56.9% (33/58) believed dental procedure to be a risk factor, and 55.2% (32/58) did not recommend screening of the oral cavity by a dentist before initiation of bisphosphonate therapy. A majority (65.5%) of them educated their patients about adverse effects. Mean knowledge scores varied with specialization (post-graduation vs. super specialization = 1.43 vs. 2; p = 0.01) but not with the duration of practice (<= 10 years vs. >10 years= 1.57 vs. 1.4; p= 0.24).

Conclusion: The practitioners in our study were oblivious to dental procedures' role in the osteonecrosis of the jaw, highlighting the need for continuing education programs regarding BRONJ for medical and dental professionals. Clinicians updated regarding evidence-based practices and working cooperatively in teams may reduce the incidence of medication-related osteonecrosis of the jaw.

Keywords: Attitude, awareness, bisphosphonates, osteonecrosis, physicians, jaw.

« Previous Next »
[1]
Ganesan K, Goyal A, Roane D. Bisphosphonate.In: StatPearls. StatPearls Publishing 2021.
[2]
Watts NB, Chesnut CH III, Genant HK, et al. History of etidronate. Bone 2020; 134: 115222.
[http://dx.doi.org/10.1016/j.bone.2020.115222] [PMID: 31911206]
[3]
Kennel KA, Drake MT. Adverse effects of bisphosphonates: Implications for osteoporosis management. Mayo Clin Proc 2009; 84(7): 632-7.
[http://dx.doi.org/10.1016/S0025-6196(11)60752-0] [PMID: 19567717]
[4]
Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 2003; 61(9): 1115-7.
[http://dx.doi.org/10.1016/S0278-2391(03)00720-1] [PMID: 12966493]
[5]
El-Ma’aita A, Da’as N, Al-Hattab M, Hassona Y, Al-Rabab’ah M, Al-Kayed MA. Awareness of the risk of developing medication-related osteonecrosis of the jaw among bisphosphonate users. J Int Med Res 2020; 48(9): 300060520955066.
[http://dx.doi.org/10.1177/0300060520955066] [PMID: 32924697]
[6]
Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014; 72(10): 1938-56.
[http://dx.doi.org/10.1016/j.joms.2014.04.031] [PMID: 25234529]
[7]
Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22(10): 1479-91.
[http://dx.doi.org/10.1359/jbmr.0707onj] [PMID: 17663640]
[8]
Frazer-Cox C. New MRONJ guidance. Br Dent J 2020; 229(3): 151.
[http://dx.doi.org/10.1038/s41415-020-2013-9] [PMID: 32811916]
[9]
Siddiqi A, Payne AG, Zafar S. Bisphosphonate-induced osteonecrosis of the jaw: A medical enigma? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009; 108(3): e1-8.
[http://dx.doi.org/10.1016/j.tripleo.2009.04.027] [PMID: 19570696]
[10]
Ferneini EM. Medication-Related Osteonecrosis of the Jaw (MRONJ). J Oral Maxillofac Surg 2021; 79(8): 1801-2.
[http://dx.doi.org/10.1016/j.joms.2021.05.014] [PMID: 34334170]
[11]
Dodson TB. The frequency of medication-related osteonecrosis of the jaw and its associated risk factors. Oral Maxillofac Surg Clin North Am 2015; 27(4): 509-16.
[http://dx.doi.org/10.1016/j.coms.2015.06.003] [PMID: 26362367]
[12]
Lau J, Ng L, Siddiqi A, Zafar S. Paediatric dentists treating children on bisphosphonates: A cross-sectional questionnaire-based study. Pediatr Dent 2019; 41(4): 285-92.
[PMID: 31439088]
[13]
Alhussain A, Peel S, Dempster L, Clokie C, Azarpazhooh A. Knowledge, practices, and opinions of ontario dentists when treating patients receiving bisphosphonates. J Oral Maxillofac Surg 2015; 73(6): 1095-105.
[http://dx.doi.org/10.1016/j.joms.2014.12.040] [PMID: 25843818]
[14]
Capocci M, Romeo U, Guerra F, et al. Medication-related osteonecrosis of the jaws (MRONJ) and quality of life evaluation: A pilot study. Clin Ter 2017; 168(4): e253-7.
[PMID: 28703840]
[15]
El Osta L, El Osta B, Lakiss S, Hennequin M, El Osta N. Bisphosphonate-related osteonecrosis of the jaw: Awareness and level of knowledge of Lebanese physicians. Support Care Cancer 2015; 23(9): 2825-31.
[http://dx.doi.org/10.1007/s00520-015-2649-1] [PMID: 25672288]
[16]
Yamori M, Tamura M, Mikami M, et al. Differences in the knowledge and experience of physicians and dentists about medication-related osteonecrosis of the jaw in osteoporotic patients. Int Dent J 2021; 71(4): 336-42.
[http://dx.doi.org/10.1016/j.identj.2020.12.005] [PMID: 33518370]
[17]
Kim JW, Jeong SR, Kim SJ, Kim Y. Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw. BMC Oral Health 2016; 16(1): 92.
[http://dx.doi.org/10.1186/s12903-016-0290-0] [PMID: 27604159]
[18]
Rahman Z, et al. A survey evaluating the awareness of MRONJ within the Birmingham GMP community. Oral Surg 2019; 12(1): 22-9.
[http://dx.doi.org/10.1111/ors.12372]
[19]
Kolur T, Nair SC, Kumar B. Osteonecrosis of maxilla secondary to bisphosphonate therapy: A case report. J Maxillofac Oral Surg 2015; 14 (Suppl. 1): 52-6.
[http://dx.doi.org/10.1007/s12663-011-0284-z] [PMID: 25838669]
[20]
Al-Mohaya MA, Al-Khashan HI, Mishriky AM, Al-Otaibi LM. Physicians’ awareness of bisphosphonates-related osteonecrosis of the jaw. Saudi Med J 2011; 32(8): 830-5.
[PMID: 21858393]
[21]
Coskun Benlidayi I, Guzel R. Oral bisphosphonate related osteonecrosis of the jaw: A challenging adverse effect. ISRN Rheumatol 2013; 2013: 215034.
[http://dx.doi.org/10.1155/2013/215034] [PMID: 23762600]
[22]
Al-Eid R, Alduwayan T, Bin Khuthaylah M, Al Shemali M. Dentists’ knowledge about medication-related osteonecrosis of the jaw and its management. Heliyon 2020; 6(7): e04321.
[http://dx.doi.org/10.1016/j.heliyon.2020.e04321] [PMID: 32760820]
[23]
Sturrock A, Preshaw PM, Hayes C, Wilkes S. Attitudes and perceptions of GPs and community pharmacists towards their role in the prevention of bisphosphonate-related osteonecrosis of the jaw: A qualitative study in the North East of England. BMJ Open 2017; 7(9): e016047.
[http://dx.doi.org/10.1136/bmjopen-2017-016047] [PMID: 28965092]
[24]
Krishnan SSV, Shetty J, Babu GS, Rajeev TP. Bisphosphonate-related osteonecrosis of the jaw: An enigma among medical practitioners. Indian J Med Paediatr Oncol 2019; 40: 257-64.
[http://dx.doi.org/10.4103/ijmpo.ijmpo_20_18]
[25]
Arora S, Ramachandra SS, Squier C. Knowledge about human papillomavirus (HPV) related oral cancers among oral health professionals in university setting-A cross sectional study. J Oral Biol Craniofac Res 2018; 8(1): 35-9.
[http://dx.doi.org/10.1016/j.jobcr.2017.12.002] [PMID: 29556461]
[26]
Ramachandra SS, Gupta VV, Mehta DS, Gundavarapu KC, Luigi N. Differential diagnosis between chronic versus aggressive periodontitis and staging of aggressive periodontitis: A cross-sectional study. Contemp Clin Dent 2017; 8(4): 594-603.
[http://dx.doi.org/10.4103/ccd.ccd_623_17] [PMID: 29326511]
[27]
Lee M, Kim K, Rhew K, Choi KH. A knowledge, attitude, and practice survey on medication safety in Korean older adults: An analysis of an ageing society. Healthcare (Basel) 2021; 9(10): 1365.
[http://dx.doi.org/10.3390/healthcare9101365] [PMID: 34683048]
[28]
Mah YJ, Kang GY, Kim SJ. Survey on awareness and perceptions of bisphosphonate-related osteonecrosis of the jaw in dental hygienists in Seoul. Int J Dent Hyg 2015; 13(3): 222-7.
[http://dx.doi.org/10.1111/idh.12122] [PMID: 25677614]
[29]
Aminu M, Phillips E, Kolanko C. The role of digital competence in CME uptake: A short communication. J Eur CME 2021; 11(1): 2019436.
[http://dx.doi.org/10.1080/21614083.2021.2019436] [PMID: 34992950]
[30]
Kawczak S, Fernandez A, Frampton B, et al. Observations from transforming a continuing education programme in the COVID-19 era and preparing for the future. J Eur CME 2021; 10(1): 1964315.
[http://dx.doi.org/10.1080/21614083.2021.1964315] [PMID: 34434609]
[31]
Patil V, Acharya S, Vineetha R, Nikhil K. Awareness about medication-related osteonecrosis of the jaw among dental professionals: A multicentre study. Oral Health Prev Dent 2020; 18(1): 505-9.
[PMID: 32016175]
[32]
Muthukrishnan A, Kumar L, Ramalingam G. Medication-related osteonecrosis of the jaw: A dentist's nightmare. BMJ Case Rep 2016; 2016
[http://dx.doi.org/10.1136/bcr-2016-214626]
[33]
Miranda-Silva W, Montezuma MA, Benites BM, Bruno JS, Fonseca FP, Fregnani ER. Current knowledge regarding medication-related osteonecrosis of the jaw among different health professionals. Support Care Cancer 2020; 28(11): 5397-404.
[http://dx.doi.org/10.1007/s00520-020-05374-4] [PMID: 32144584]
[34]
Wan JT, Sheeley DM, Somerman MJ, Lee JS. Mitigating osteonecrosis of the jaw (ONJ) through preventive dental care and understanding of risk factors. Bone Res 2020; 8: 14.
[http://dx.doi.org/10.1038/s41413-020-0088-1] [PMID: 32195012]
[35]
Sreenivasan VP, Ganganna A, Rajashekaraiah PB. Awareness among intensive care nurses regarding oral care in critically ill patients. J Indian Soc Periodontol 2018; 22: 541-5.

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy